2a.01) Select the data sources for which the measure is listed.

Electronic health data, electronic health records

2a.02) If an existing dataset was used, identify the specific dataset.

For reliability testing, we used data from the Michigan Hospital Medicine Safety Consortium (HMS). HMS is a collaborative quality initiative sponsored by Blue Cross Blue Shield of Michigan (<a href="https://mi-hms.org/">https://mi-hms.org/</a>). HMS includes 62 non-governmental hospitals throughout the state of Michigan. In July 2017, HMS hospitals joined in the "Antimicrobial Use Initiative" to collect patient-level data related to hospitalized, medical patients treated for urinary tract infection (UTI) (<a href="https://mi-hms.org/quality-initiatives/antimicrobial-use-initiative">https://mi-hms.org/quality-initiatives/antimicrobial-use-initiative</a>). 1,2

For all analyses included in this measure submission, data from HMS are censored as of March 31, 2020, at which time 49 hospitals had contributed data to the dataset.

The dataset includes chart abstracted data, such as:

- Patient demographics (e.g., age, admission, and discharge dates)
- Positive urine culture information (e.g., organisms)
- Presence of signs or symptoms of a UTI within the period of the day prior to the urine culture being collected through two days after urine culture being collected (day -1 to +2 where the urine culture collection date is day 0)
  - Physical exam findings (e.g., costovertebral angle tenderness)
  - Vital signs (e.g., fever)
  - Documented symptoms (e.g., dysuria)
  - Laboratory findings (e.g., leukocytosis)
- Antibiotic use during admission and on discharge
- Urinary catheter use
- Comorbidities including diabetes, end stage renal disease (ESRD), dementia, admission from a skilled nursing facility/long term care facility
- 30-day adverse events (emergency department visit, mortality, *Clostridioides difficile* infection, antibiotic associated side effects) documented in the medical record
- 30-day adverse events collected via telephone interview (conducted 30-days post discharge)

## References:

- Petty LA, Vaughn VM, Flanders SA, et al. Risk Factors and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized Patients. *JAMA Intern Med.* 2019;179(11):1519– 1527.
- Petty LA, Vaughn VM, Flanders SA, et al. Assessment of Testing and Treatment of Asymptomatic Bacteriuria Initiated in the Emergency Department. *Open Forum Infect Dis*. 2020 Nov 3;7(12):ofaa537.

2a.03) Provide the dates of the data used in testing.

07-01-2017 to 03-31-2020

2a.04) Select the levels of analysis for which the measure is tested.

Facility

2a.05) List the measured entities included in the testing and analysis (by level of analysis and data source).

**Table 1. Characteristics of Participating Hospitals** 

Hospital Characteristic	HMS Hospitals n=49; n (%)	All Michigan Hospitals <sup>1</sup> n=127; n (%)
Academic Hospital <sup>1</sup>	40 (82%)	74 (58%)
Location <sup>2,3</sup>	*	*
Metropolitan	40 (82%)	71 (56%)
Micropolitan	8 (16%)	24 (19%)
Rural	1 (2%)	32 (25%)
Profit Type <sup>2</sup>	*	*
Non-Profit	45 (92%)	116 (59%)
For profit	4 (8%)	9 (33%)
Government	0 (0%)	2 (2%)
Bed Size (Staffed beds) <sup>4</sup>	*	*
≤50	2 (4%)	46 (36%)
51-100	4 (8%)	21 (17%)
101-200	9 (18%)	16 (13%)
>200	34 (69%)	44 (35%)

<sup>\*</sup>Cells intentionally left empty

Data compiled from the following sources:

Children's hospitals

<sup>&</sup>lt;sup>1</sup> List of Michigan Hospitals compiled from the Michigan Health & Hospital Association mha.org/about/our-hospitals Accessed January 3, 2022

<sup>&</sup>lt;sup>2</sup> U.S. Census Bureau, Michigan: 2020 Core Based Statistical Areas and Counties https://www2.census.gov/programs-surveys/metro-micro/reference-maps/2020/state-maps/26 Michigan 2020.pdf

<sup>&</sup>lt;sup>3</sup> U.S. Census Bureau, Core based statistical areas (CBSAs), metropolitan divisions, and combined statistical areas (CSAs) <a href="https://www.census.gov/geographies/reference-files/time-series/demo/metro-micro/delineation-files.html">https://www.census.gov/geographies/reference-files/time-series/demo/metro-micro/delineation-files.html</a>

<sup>&</sup>lt;sup>4</sup> American Hospital Directory, Individual Hospital Statistics for Michigan <a href="https://www.ahd.com/states/hospital">https://www.ahd.com/states/hospital</a> MI.html

<sup>§</sup>The following types of hospitals were excluded:

- Long-term acute care hospitals
- Psychiatric/mental health/substance abuse hospitals
- Rehabilitation hospitals
- Surgical hospitals
- Those providing only specialty services (i.e., cardiac hospital)

Alt-text for Table 1: Participating HMS hospitals (N=49) are compared to all Michigan hospitals (N=127) for proportion classified as academic; location; profit type; and bed size (staffed beds). Relative to all Michigan hospitals, more HMS hospitals were academic (82% vs 58%), located in metropolitan areas (82% vs 56%), were non-profit (92% vs 59%), and had >200 beds (69% vs 35%).

2a.06) Identify the number and descriptive characteristics of patients included in the analysis (e.g., age, sex, race, diagnosis), separated by level of analysis and data source; if a sample was used, describe how patients were selected for inclusion in the sample.

Between 7/1/2017 and 3/31/2020 there were 13,805 hospitalized patients treated for UTI across 49 HMS hospitals. All 13,805 patients were used to test validity and reliability of the inappropriate diagnosis of UTI measure. Of the 13,805 patients treated for UTI, 23.2% (3,197) were assessed to be inappropriately diagnosed with UTI. Reliability and validity were assessed at the hospital level and validity was assessed at the encounter (i.e., patient) level. Descriptive characteristics of the entire UTI cohort are as follows:

Table 2. Descriptive characteristics of the entire UTI cohort, patients with appropriate diagnosis of UTI, and patients with inappropriate diagnosis of UTI

Characteristic	Entire UTI Cohort, n (%)	Appropriate Diagnosis, n (%)	Inappropriate Diagnosis, n (%)
Gender	*	*	*
Male	4097 (29.7%)	3311 (31.2%)	786 (24.6%)
Female	9702 (70.3%)	7292 (68.7%)	2410 (75.4%)
Race	*	*	*
White	10257 (74.3%)	7885 (74.3%)	2372 (74.2%)
Black	2945 (21.3%)	2251 (21.2%)	694 (21.7%)
Asian	74 (0.5%)	64 (0.6%)	10 (0.3%)
American Indian	37 (0.3%)	26 (0.2%)	11 (0.3%)
Native Islander	22 (0.2%)	18 (0.2%)	4 (0.1%)
Other	227 (1.6%)	186 (1.8%)	41 (1.3%)
Unknown	190 (1.4%)	143 (1.3%)	47 (1.5%)
Age (years)	*	*	*
18-30	494 (3.6%)	445 (4.2%)	49 (1.5%)
31-40	453 (3.3%)	399 (3.8%)	54 (1.7%)
41-50	624 (4.5%)	515 (4.9%)	109 (3.4%)
51-60	1235 (8.9%)	999 (9.4%)	236 (7.4%)
61-70	2435 (17.6%)	1895 (17.9%)	540 (16.9%)
71-80	3463 (25.1%)	2665 (25.1%)	798 (25.0%)
80-90	3709 (26.9%)	2706 (25.5%)	1003 (31.4%)
91-100	1316 (9.5%)	929 (8.8%)	387 (12.1%)

Characteristic	Entire UTI Cohort, n (%)	Appropriate Diagnosis, n (%)	Inappropriate Diagnosis, n (%)
100+	76 (0.6%)	55 (0.5%)	21 (0.7%)
Insurance Status	*	*	*
Private	1316 (9.5%)	1077 (10.2%)	239 (7.5%)
Medicare	10165 (73.6%)	7600 (71.6%)	2565 (80.2%)
Medicaid	1209 (8.8%)	1012 (9.5%)	197 (6.2%)
Uninsured	114 (0.8%)	105 (1.0%)	9 (0.3%)
Comorbidities	*	*	*
Presence of urinary catheter	1876 (13.6%)	1426 (13.4%)	450 (14.1%)
Renal disease	5643 (40.9%)	4303 (40.6%)	1340 (41.9%)
Liver disease	811 (5.9%)	636 (6.0%)	175 (5.5%)
Congestive heart failure	3241 (23.5%)	2403 (22.7%)	838 (26.2%)
Chronic obstructive pulmonary			
disease	2507 (18.2%)	1889 (17.8%)	618 (19.3%)
Home oxygen	619 (4.5%)	457 (4.3%)	162 (5.1%)
Structural lung disease	0 (0%)	0 (0%)	0 (0%)
Current/Former smoker	6489 (47%)	5111 (48.2%)	1378 (43.1%)
Cancer	2778 (20.1%)	2143 (20.2%)	635 (19.9%)
Immune compromise	95 (0.7%)	74 (0.7%)	21 (0.7%)
Diabetes mellitus	5331 (38.6%)	4111 (38.8%)	1220 (38.2%)
Sepsis	3774 (27.3%)	3551 (33.5%)	223 (7%)
Severe Sepsis	339 (2.5%)	339 (3.2%)	0 (0%)

<sup>\*</sup>Cells intentionally left empty

Alt-text for Table 2. Descriptive characteristics of the entire UTI cohort, patients with appropriate diagnosis of UTI, and patients with inappropriate diagnosis of UTI, including gender, race, insurance status, and co-morbidities.

Hospitals within HMS use the following case identification strategy to determine patients to abstract for HMS:

- Data collection involves abstraction of eligible cases every two weeks.
- To minimize sampling bias, abstractors are expected to select cases from every day during a two-week time period, including weekends.
- The list of cases eligible for abstraction is created using the below protocol
  - o For each two-week period, a list of patients admitted to all medical services is created
    - For inappropriate diagnosis of UTI, this list is generally a list of all positive urine cultures
    - If possible, hospitals apply additional electronic filters to the dataset to screen for inclusion/exclusion criteria. For example, they may exclude patients from the "inappropriate diagnosis of UTI" list if they also had a discharge diagnosis of pneumonia or were cared for on a non-medicine service.
      - All inclusion/exclusion criteria that are not electronically applied prior to list generation will require manual screening during case review
    - The list of potentially eligible patients is then organized chronologically by date and time of discharge.

- For each discharge day, the first patient on the chronological list is reviewed for inclusion. If excluded, the next patient is reviewed.
- This process is repeated, with patients reviewed from the chronological list ensuring that cases are distributed evenly across the two-week timeframe – meaning there are discharge dates across all days of the week – until all cases are identified and abstracted.

We do not report encounter-level reliability as we report encounter-level validity. Please see the validity documents for additional information.

2a.07) If there are differences in the data or sample used for different aspects of testing (e.g., reliability, validity, exclusions, risk adjustment), identify how the data or sample are different for each aspect of testing.

All data analysis was performed on the same dataset.

Table 3. Description of samples utilized to determine hospital-level and patient-level reliability and empirical validity

Type of Testing	Sample Utilized
Hospital-Level	Entire HMS UTI Dataset (based on case identification protocol outlined in
Reliability and Empirical	2a.06)
Validity <sup>1</sup>	
Encounter-Level	Data Audit: Review of a random, consecutive subset of 50 encounters
Reliability <sup>1</sup>	within the cohort, representing cases from 29 of 46 participating hospitals.
	Structured Implicit Case Review: Seventeen cases, pseudo-randomly
	selected, for in-depth review by 2-4 physicians to confirm case classification
	(appropriate versus inappropriate diagnosis)

<sup>&</sup>lt;sup>1</sup>Please see validity documents for further information.

Alt-text for Table 3: The entire HMS UTI dataset was used to determine hospital-level reliability and empirical validity. Encounter-level reliability was determined by data audit and structured implicit case reviews.

2a.08) List the social factors that were available and analyzed.

As this is a process measure, no risk adjustment was performed (including for social factors).

2a.09) Select the level of reliability testing conducted.

Patient or Encounter-Level Accountable Entity Level (e.g., signal-to-noise)

2a.10) For each level of reliability testing checked above, describe the method of reliability testing and what it tests.

## **Patient or Encounter Level**


Please see validity testing section for encounter-level validity.

## **Accountable Entity Level**

Signal-to-noise analysis was performed using a mixed-effect logistic model ran as an empty model such that the only effects in the model were the overall intercept and the hospital specific intercepts. This model enabled for the calculation of the hospital variance (signal), the total variance, and the within hospital variance (noise). Based on the hospital variance and the within hospital variance, an intraclass correlation was calculated. The intraclass correlation was utilized within the Spearman Brown formula in two ways: (A) to calculate the reliability for the entire hospital cohort using the median number of case abstractions for the cohort and (B) to understand minimum case abstracts necessary to achieve predetermined reliability thresholds of 0.6, 0.7, 0.8, and 0.9.

2a.11) For each level of reliability testing checked above, what were the statistical results for reliability testing?

Distribution of percentage of patients inappropriately diagnosed with UTI by hospital with 95% confidence intervals is demonstrated below. These data are based on the 4 quarters preceding March 2020 and include only hospitals that provided data during all four quarters.



Alt-text for Figure: Distribution of percentage of patients inappropriately diagnosed with UTI by hospital with 95% confidence intervals ranges from 4.2% to 37.3%. Data are based on the 4 quarters preceding March 2020 and include only hospitals that provided data during all four quarters (N=39 hospitals).

From these data, we were able to calculate the following:

Hospital Variance (signal): 0.225271

Total Variance: 3.5151414

Within Hospital Variance (noise): 3.28987

Based on this information, an intraclass correlation (ICC) was calculated. This ICC represents the reliability of the cohort if a single measurement (case abstraction) per hospital were included.

A. The Spearman Brown Prophecy allows to an estimation of reliability after adjusting the number of measurements. We can use this formula to estimate the reliability of the measure within the cohort after adjusting the input (in this case the number of case abstractions per site). 1,2 The Spearman Brown Formula states the following:

Reliability<sub>new</sub> = (n\*r)/(1+[n-1]\*r) where n is the number of inputs and r is the prior reliability.

Adapting to the formula to our variables suggests the following:

Reliability<sub>new</sub> = (number of case reviews\*ICC)/(1+[number of case reviews-1]\*ICC)

The median case abstraction counts for the entire cohort was applied to the Spearman Brown Formula to obtain the overall reliability for the cohort.

Median case abstractions: 133 (IQR 92-154)

Reliability: (133\*0.0640859)/(1+(133-1)\*0.0640859)=0.901

- 1. Spearman, C. (1910), Correlation Calculated From Faulty Data. *British Journal of Psychology*, 1904-1920, 3: 271-295.
- 2. Warrens MJ. Transforming intraclass correlation coefficients with the Spearman-Brown formula. *J Clin Epidemiol*. 2017 May;85:14-16
- B. The ICC was then applied to the Spearman Brown Formula to calculate the minimum number of cases to achieve pre-specified reliability thresholds based on the outcome distribution of the entire cohort.

Table 1. Number of annual cases needed to achieve each reliability threshold.

Reliability		Number of
		annual cases
		needed
	0.6	22
	0.7	35
	0.8 (standard)	59
Г	0.9	132

Alt-Text for Table 1. In order to achieve a desired reliability of 0.8, each hospital would need to abstract 63 cases annually.

2a.12) Interpret the results, in terms of how they demonstrate reliability.

A. Based on signal-to-noise analysis, we found that reliability of the measure across the entire hospital cohort was strong (0.90), meeting the threshold for reliability for measures considered to be high stakes.

B. Using the current HMS cohort as a representative example, the minimum number of case abstracts per hospital per year to meet pre-specified reliability thresholds of 0.7 and 0.8 are highly attainable. Within a cohort of 40 HMS hospitals participating in 2019, 90% of hospitals were able to abstract the minimum of 59 cases to achieve 0.8 reliability. Of those that could not abstract the required number of cases, hospital bed sizes were 49 beds, 68 beds, 75 beds, and 133 beds. Ninety-five percent of hospitals could abstract the 35 cases/year necessary to achieve 0.7 reliability, and all but one could reach the abstraction threshold for 0.6 reliability. Of the two hospitals unable to achieve abstraction thresholds for 0.7 reliability (75 beds and 133 beds), one hospital over-sampled casers for an alternative measure, and the other had challenges with data abstractor hiring. This cohort of 40 hospitals participating in 2019 was selected as this represented the last year of complete data collection prior to the COVID-19 pandemic.